Who Paid My Doc
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlle
Research payments
$849,222
Through program year 2020, $849,222 in research payments was reported against A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlle, across 104 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $43,181 | 7 |
| 2019 | Research | $806,041 | 97 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Richard Furie Rego Park, NY Named on 6 payments
- Cynthia Aranow Manhasset, NY Named on 5 payments
- Anca Askanase New York, NY Named on 5 payments
- Soumya Chatterjee Cleveland, OH Named on 4 payments
- Nathaniel Neal Los Alamitos, CA Named on 4 payments
- David Goddard Brooklyn, NY Named on 4 payments
- Maria Carpintero Miami, FL Named on 4 payments
- Vikas Majithia Jackson, MS Named on 3 payments
- Norman Gaylis Aventura, FL Named on 3 payments
- Deborah Parks Saint Louis, MO Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.